



Monday 22nd March 2010

Rebecca Trowman
Technology Appraisal Project Manager
National Institute for Health and Clinical Excellence
MidCity Place
71 High Holborn
LONDON
WC1V 6NA

BY E-MAIL

Dear Rebecca,

**SINGLE TECHNOLOGY APPRAISAL –
Bevacizumab in combination with oxaliplatin and either 5-fluorouracil or
capecitabine for the treatment of metastatic colorectal cancer**

The revised PAS template dated the 9th March 2010 contains the deterministic results of the economic analysis with the changes as described in Roche’s response to the ACD incorporated in the analysis.

For completeness the probabilistic ICER’s are now provided below alongside the deterministic results that were previously reported in the aforementioned PAS template. It can be seen that the mean probabilistic ICERs mirror those of the deterministic analysis.

Analysis	Deterministic ICERs	Probabilistic ICERs
<i>With APAS applied:</i>		
B-XELOX vs XELOX	£29,975	£29,625
B-FOLFOX-6 vs FOLFOX-6	£24,604	£24,315
<i>Without APAS applied:</i>		
B-XELOX vs XELOX	£104,870	£104,578
B-FOLFOX-6 vs FOLFOX-6	£108,267	£108,346

Figures 1 to 3 below display graphically the probabilistic sensitivity analysis results when the APAS is applied.

Roche Products Limited

6 Falcon Way
Shire Park
Welwyn Garden City
Hertfordshire
AL7 1TW

Healthcare Management

Registered Number
100674 London

Tel:

Fax:

Mobile:

E-mail:



Figure 1: B-XELOX vs XELOX with APAS





Figure 2: B-FOLFOX-6 vs FOLFOX-6



Roche Products Limited

6 Falcon Way
Shire Park
Welwyn Garden City
Hertfordshire
AL7 1TW

Healthcare Management

Registered Number
100674 London

Tel:


Fax:

Mobile:

E-mail:



Figure 3: CEAC



Regards,